Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of IDEC-C2B8 in Childhood-onset Refractory Nephrotic Syndrome (RCRNS02)
jRCT2091220021Phase 1Completed
- Sponsor
- Kobe University Hospital
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rituximab in Idiopathic nephrotic syndrome (INS), sponsored by Kobe University Hospital. Primary endpoint: Pharmacokinetic profiles of rituximab. Started Sep 2008; status: completed.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on jRCT2091220021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220021.